LYTIR

Insider · SEC Form 4 · Chief Executive Officer

John T. Treace

Filed with the SEC as Treace John T.; the order above is the one the filer's own signature uses.

In the 12 months to Nov 19, 2026, on the open market: bought $247K of TMCI. Filed a median of 1 business day after the trade.

Open-market purchases and sales this filer reported on SEC Form 4, by the day traded. Insiders have two business days to file. A sale marked 10b5-1 was made under a plan adopted in advance. How to read these

  1. TMCIBought: TREACE MEDICAL CONCEPTS, INC. Aug 24, 2026 11,000 shares filed Aug 24, 2026 7,404,383 shares held directly after, as filed filing $48K
  2. TMCIBought: TREACE MEDICAL CONCEPTS, INC. Aug 21, 2026 5,000 shares filed Aug 24, 2026 7,393,383 shares held directly after, as filed filing $22K
  3. TMCIBought: TREACE MEDICAL CONCEPTS, INC. Aug 20, 2026 39,944 shares filed Aug 24, 2026 7,388,383 shares held directly after, as filed filing $177K

Source: SEC Form 4 filings. Value is shares × the price reported on the filing; a filing whose price failed Lytir's check against the market price is left out, and a trade that related owners reported on separate forms is counted once. Filings can be late, amended or wrong at the source; see methodology.

Stakes filed (13D/13G)

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Filings made under this filer's SEC CIK in the same 12 months, newest first; the figure is the percentage the filing states. Every recent 13D and 13G

  1. TMCIJohn T. Treace filed Aug 12, 2026 Schedule 13G/A passive issuer: Treace Medical Concepts, Inc. filing 19.2%